Phase III CheckMate-67T trial of subcutaneous Opdivo + hyaluronidase meets endpoints in advanced or metastatic ccRCC

Imaging technique accurately detects ccRCC

A new study led by investigators from the UCLA Health Jonsson Comprehensive Cancer Center has demonstrated a new, non-invasive imaging technique can accurately detect clear-cell renal cell carcinoma, the most common form of kidney cancer.

October 04, 2024

Vol.50 No.37

Drugs & Targets

FDA approves neoadjuvant/adjuvant Opdivo for resectable NSCLC

FDA approved Opdivo (nivolumab) with platinum-doublet chemotherapy as neoadjuvant treatment, followed by single-agent Opdivo after surgery as adjuvant treatment, for adults with resectable (tumors ≥ 4 cm and/or node positive) non-small cell lung cancer and no known epidermal growth factor receptor mutations or anaplastic lymphoma kinase rearrangements.

October 04, 2024

Vol.50 No.37

Regulatory News

ODAC votes overwhelmingly in support of PD-L1 expression as predictive biomarker for efficacy of checkpoint inhibitors
Vote applies across drugs and indications

The FDA Oncologic Drugs Advisory Committee on Sept. 26 voted that PD-L1 inhibitors should not be indicated for patients with PD-L1-negative gastric/gastroesophageal junction adenocarcinoma and esophageal squamous cell carcinoma.

Ten-year follow-up data shows Opdivo + Yervoy improves OS in advanced melanoma

Ten-year follow-up data from CheckMate-067, a randomized, double-blind, phase III clinical trial showed continued durable improvement in survival with first-line Opdivo (nivolumab) plus Yervoy (ipilimumab) therapy and Opdivo monotherapy, versus Yervoy alone, in patients with previously untreated advanced or metastatic melanoma.

September 20, 2024

Vol.50 No.35

Clinical Roundup

Opdivo + Yervoy improves OS for advanced hepatocellular carcinoma in phase III trial

Bristol Myers Squibb presented results from the phase III CheckMate-9DW trial evaluating the dual immunotherapy combination of Opdivo (nivolumab) plus Yervoy (ipilimumab) compared to investigator’s choice of lenvatinib or sorafenib as a first-line treatment for patients with unresectable hepatocellular carcinoma. Results from the study were featured in a late-breaking oral presentation at the 2024 American Society of Clinical Oncology Annual Meeting.

June 07, 2024

Vol.50 No.23

Clinical Roundup

Updated analyses from 3 phase III trials continue to support Opdivo and its combinations for NSCLC

Bristol Myers Squibb announced results from three updated analyses from the CheckMate-77T, CheckMate-816, and CheckMate-9LA studies supporting Opdivo (nivolumab) and Opdivo-based combinations in early stage and advanced non-small cell lung cancer. Data were presented at the 2024 American Society of Clinical Oncology Annual Meeting.

June 07, 2024

Vol.50 No.23

Phase III CheckMate-67T trial of subcutaneous Opdivo + hyaluronidase meets endpoints in advanced or metastatic ccRCC

YOU MAY BE INTERESTED IN

Imaging technique accurately detects ccRCC

FDA approves neoadjuvant/adjuvant Opdivo for resectable NSCLC

ODAC votes overwhelmingly in support of PD-L1 expression as predictive biomarker for efficacy of checkpoint inhibitors
Vote applies across drugs and indications

Ten-year follow-up data shows Opdivo + Yervoy improves OS in advanced melanoma

Opdivo + Yervoy improves OS for advanced hepatocellular carcinoma in phase III trial

Updated analyses from 3 phase III trials continue to support Opdivo and its combinations for NSCLC

Renew today!

Subscriber content

Never miss an issue!

Login

Phase III CheckMate-67T trial of subcutaneous Opdivo + hyaluronidase meets endpoints in advanced or metastatic ccRCC

YOU MAY BE INTERESTED IN

Imaging technique accurately detects ccRCC

FDA approves neoadjuvant/adjuvant Opdivo for resectable NSCLC

ODAC votes overwhelmingly in support of PD-L1 expression as predictive biomarker for efficacy of checkpoint inhibitorsVote applies across drugs and indications

Ten-year follow-up data shows Opdivo + Yervoy improves OS in advanced melanoma

Opdivo + Yervoy improves OS for advanced hepatocellular carcinoma in phase III trial

Updated analyses from 3 phase III trials continue to support Opdivo and its combinations for NSCLC

Never miss an issue!

Login

ODAC votes overwhelmingly in support of PD-L1 expression as predictive biomarker for efficacy of checkpoint inhibitors
Vote applies across drugs and indications